GCVRZ Dutch Tender Results
Sanofi (Ticker: SNY) announced the final Dutch tender results of its purchase of the CVRs (Ticker: GCVRZ). The company was attempting to buy back up to ~ 30% (86,766,040 shares) of its CVRs, but only 40,025,805 shares were tendered. So everyone who tendered will get paid out $1.75 on October 11. I was expecting a relatively low tender, but not this low. I know a few people with received the CVRs from the Genzyme acquisition and no one tendered. They are all waiting for the Lemtrada story to play out. I purchased the CVRs on September 28 at $1.68, which equates to a 4.17% return over a 14 day period (~ 107% annualized return). It was only a 4% position, but still a nice little pay day. I'm still long the CVRs I received from the Genzyme acquisition.
2 Comments:
Great investment. In case you're interested, here is a short article I wrote on the topic:
http://seekingalpha.com/article/1095761-gcvrz-a-potential-16-bagger-worth-the-risk
I believe your expectation of a decision by the FDA in Q1'13 is a bit aggressive. The company received a Refuse to File notification from the FDA last year, which pushes back the approval process. I would factor in a decision by the FDA in Q4'13.
Post a Comment
<< Home